Breaking News, Collaborations & Alliances

Rakuten Medical, Hikma Ink Alluminox Platform Pact

Hikma has an exclusive license to commercialize products in Rakuten medical's pipeline using its photoimmunotherapy technology platform.

Rakuten Medical Inc., a  global biotechnology company developing and commercializing precision, cell targeting therapies based on its Alluminox platform, entered into an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, for the Middle East and North Africa (MENA). Hikma has an exclusive license to commercialize products in Rakuten’s medical’s pipeline using its photoimmunotherapy technology platform, Alluminox, in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters